• Minomic International Ltd (Minomic) is a biomarker research company whose focus is commercialising non-invasive biomarkers for diagnosis and treatment of major diseases, one for Prostate Cancer and one for Type 2 Diabetes

• Both diagnostic products are urine based tests and will offer significant advantages over the dominant, more invasive screening methods currently used for detecting each disease

• Minomic has contractually based, exclusive rights to the use of a mouse monoclonal antibody for prostate cancer detection 

• Worldwide, more than 670,000 men are diagnosed with prostate cancer every year

• The worldwide market for the gold standard prostate cancer test, the PSA test, is currently estimated at more than 65 million tests per year costing approximately US$3 billion annually

• We intend to become a major supplier to the diagnostic market by way of test kits manufactured and marketed by Minomic OR we will sell that opportunity and capture a significant annual royalty on ultimate sales that will provide funding for shareholder returns and other projects

PROSTATE CANCER TESTING SET TO INCREASE
Prostate Cancer tests are set to increase dramatically with the aid of a new diagnostic being developed...

MINOMIC INTERNATIONAL TO COMMERCIALISE PROSTATE CANCER AND DIABETES (TYPE 2) DIAGNOSTICS
Minomic International Limited has commenced its international marketing....